Novavax and SIPL to Develop 1 Billion COVID-19 Vaccine Doses for India, Other Countries

Days after Novavax, Inc. announced its experimental COVID-19 vaccine candidate produced antibodies in healthy patients in a clinical study, the company announced a license agreement with Serum Institute of India Private Limited (SIPL) to develop up to 1 billion doses of the preventative drug in India and other countries.